STOCK TITAN

Arrowhead (ARWR) Form 144 Filing Details Proposed Sale of 9,389 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

This Form 144 notice states that 9,389 shares of common stock are proposed for sale through Merrill Lynch on 08/15/2025, with an aggregate market value of $187,750.05. The filing lists the number of shares outstanding as 138,257,550 and names the exchange as NASDAQ.

The securities were acquired as compensation from James Hamilton on multiple dates between 01/04/2022 and 01/04/2025, with specified lot sizes included. The filer also reported a recent sale of 611 shares on 08/13/2025 for gross proceeds of $12,190.05. The form includes the standard attestation that the person signing does not possess undisclosed material adverse information.

Positive

  • Required disclosure provided: the filing specifies broker, planned sale date, number of shares, and aggregate market value
  • Acquisition history listed: each lot shows acquisition date and that shares were received as compensation

Negative

  • None.

Insights

TL;DR Routine insider Form 144 disclosing proposed resale of compensation-issued shares through a broker on NASDAQ.

The filing documents a proposed sale of 9,389 common shares via Merrill Lynch scheduled for 08/15/2025 and reports prior sales activity on 08/13/2025. Acquisition records show the shares were granted as compensation across multiple dates and tranches from 2022 to 2025. From a compliance perspective, the form appears to provide required transaction, acquisition and broker details and includes the attestation regarding material nonpublic information.

TL;DR An insider is selling previously granted compensation shares; disclosure is standard and informative for governance monitoring.

The report lists the holder as James Hamilton and details multiple compensation grants that underlie the shares to be sold. It also discloses a recent small sale and provides broker and scheduling information. This level of disclosure supports transparency around insider liquidity events but does not itself state any change in company operations or governance policies.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Form 144 for ARWR disclose?

The form discloses a proposed sale of 9,389 common shares via Merrill Lynch on 08/15/2025 with an aggregate market value of $187,750.05.

Who acquired the shares being sold according to this filing?

The shares were listed as acquired from James Hamilton as compensation on multiple dates from 01/04/2022 through 01/04/2025.

Were there any recent sales reported in the filing?

Yes. The filing reports a sale of 611 shares on 08/13/2025 for gross proceeds of $12,190.05.

Which broker and exchange are named for the proposed sale?

The broker is Merrill Lynch (75 Rockefeller Plz, New York, NY) and the securities exchange is listed as NASDAQ.

Does the filing state any undisclosed material information?

The filer signs the standard attestation representing they do not know any undisclosed material adverse information regarding the issuer.
Arrowhead Pharma

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Latest SEC Filings

ARWR Stock Data

9.14B
129.83M
4.43%
77.49%
9.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA